Breakthrough in Cancer Gene Therapy: Dual-Targeting Dendrimer Gel Nanoparticles Show Promising Therapeutic Outcomes

Researchers at the Missouri University of Science and Technology have developed a new type of dendrimer gel nanoparticle that targets two key proteins in triple-negative breast cancer (TNBC) cells, urokinase-type plasminogen activator receptor (uPAR) and ribonucleotide reductase R2 (R2). This novel design allows the nanoparticles to deliver the antisense oligonucleotide GTI-2040 (GTI) more effectively, reducing R2 expression by 83.1% and inducing 30% TNBC cell death.

Key Takeaways:

• The dual-functional dendrimer gel nanoparticles, GDP-uPA/GTI, were designed to target both TNBC cells and cancer-associated stromal cells by leveraging uPA-uPAR interactions.
• The nanoparticles demonstrated good biocompatibility, with an average size of 16.45 nm, and enhanced GTI delivery by 3.4-fold in TNBC cells and by 4.8-fold in stromal cells compared to GTI alone.
• In a TNBC xenograft model, GDP-uPA/GTI significantly inhibited tumor growth by 50.5%.
• The research highlights the unique design of the dual-functional dendrimer gel nanoparticles and their dual-targeting efficacy, demonstrating their potential as a promising therapeutic strategy for TNBC.

Statistics:

• TNBC accounts for approximately 15% of breast cancers.
• The nanoparticles demonstrated enhanced GTI delivery by 3.4-fold in TNBC cells and by 4.8-fold in stromal cells.
• GDP-uPA/GTI reduced R2 expression by 83.1% and induced 30% TNBC cell death.
• The nanoparticles had an average size of 16.45 nm.

Sources:

• Brian Wang, News Editor for Nanotechnology Weekly, based on research by:

+ Da Huang, Linda and Bipin Doshi Dept. of Chemical and Biochemical Engineering, Missouri University of Science and Technology

+ Hsin-Yin Chuang, Lin Qi, Vidit Singh, Anna Chernatynskaya, Yue-Wern Huang, and Hu Yang

+ "Highly Adaptable Dendrimer Gel Nanoparticles with Dual Targeting of uPAR and Ribonucleotide Redductase R2 for Better Retention and Improved Therapeutic Outcomes in Triple-Negative Breast Cancer." ACS Applied Materials & Interfaces, 2025.